Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia.

Article Details

Citation

Copy to clipboard

Devito F, Zito A, Ricci G, Carbonara R, Dentamaro I, Cortese F, Carbonara S, Ciccone MM

Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia.

Pharmacol Res. 2015 Dec;102:168-75. doi: 10.1016/j.phrs.2015.09.021. Epub 2015 Oct 8.

PubMed ID

26455563 [ View in PubMed

]

Abstract

Statin treatment represents the gold standard in the reduction of low-density lipoprotein cholesterol and cardiovascular risk. Although statin therapy is generally well tolerated, some patients fail to achieve the target level of low-density lipoprotein cholesterol or discontinue the treatment for the occurrence of adverse events. In recent years new lipid-modifying agents have been studied to overcome these limitations and to reduce low-density lipoprotein cholesterol plasma levels. Alirocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9, thereby preventing its interaction with low density lipoprotein receptors. Several trials have been conducted in the last few years to evaluate long-term effects of this new molecule on low-density lipoprotein cholesterol levels and cardiovascular risk.

DrugBank Data that Cites this Article

Drugs

Alirocumab

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Alirocumab	Proprotein convertase subtilisin/kexin type 9	Protein	Humans	Yes	Inhibitor	Details